What issues should patients taking ponatinib pay attention to?

Ponatinib is an oral tyrosine kinase inhibitor mainly used to treat patients with chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) who are resistant to other tyrosine kinase inhibitors. During medication, patients need to pay attention to many aspects to ensure efficacy and reduce potential risks.

Dosage and medication specifications are very important. The dosage of ponatinib is usually adjusted according to the doctor's prescription, and the dosage cannot be increased or decreased at will. Overdose may increase the risk of thrombotic events, bleeding, and liver damage, while underdosing may result in reduced therapeutic efficacy. Patients should take the medicine at a fixed time every day, and try to take it with food to keep the blood concentration stable.

Cardiovascular and thrombotic risk monitoring is key. Ponatinib may cause arterial and venous thrombotic events, including myocardial infarction, stroke, and deep vein thrombosis. Therefore, patients should assess cardiovascular risk factors, such as hypertension, hyperlipidemia, or diabetes, before taking medication, and regularly monitor blood pressure, electrocardiogram, and blood lipid levels during medication. If symptoms such as chest pain, difficulty breathing, or swelling of limbs occur, seek medical attention immediately.

Monitoring of liver and kidney function and hematological indicators cannot be ignored. Ponatinib may cause adverse reactions such as increased liver enzymes and decreased platelets or white blood cells. Patients should check their liver and kidney function and blood routine before taking medication, and review them regularly during treatment so that abnormal indicators can be discovered in time and the medication plan can be adjusted.

Combination medication and lifestyle management also need attention. Patients should inform their doctors about all prescription, over-the-counter, and supplements they are taking and avoid taking them with medications that may increase the risk of bleeding or blood clots. In addition, maintaining a healthy diet, exercising moderately, quitting smoking and limiting alcohol consumption can help reduce the risk of cardiovascular events and improve the safety of treatment. Following the above precautions can ensure the efficacy and safety of ponatinib to the greatest extent.

Reference link:https://www.drugs.com